HBM4003
Phase 1Small molecule
HBM4003 is one of 10 small molecule programs targeting Other Solid Tumors. It is currently in Phase 1.
1
Indications
5
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Other Solid Tumors
#DrugCompanyPhaseTrials
1Beyfortus
BeiGenePhase 2
Erbitux
IImclone
Phase 2
JAB 21822
AAllist Pharmaceuticals, Inc.
Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 1
MCLA-129
BBetta Pharmaceuticals Co., Ltd.
Phase 2
BL-B01D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 1
Neladalkib (NVL-655)
NNuvalent Inc.
Phase 2
HBM4003
HHarbour BioMed (Guangzhou) Co. Ltd.
Phase 1
HQP1351
Ascentage Pharma Group Inc.Phase 1
Jideytro
NNuvalent Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Other Solid Tumors2 trials
Toripalimab1 trial
Anti-PD-1 Antibody1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HBM4003. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details